New Use of Old Drugs for Zika Virus

老药新用途对抗寨卡病毒

基本信息

  • 批准号:
    9412543
  • 负责人:
  • 金额:
    $ 23.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2019-07-31
  • 项目状态:
    已结题

项目摘要

Abstract: Majority of flaviviruses are significant human pathogens. Zika virus (ZIKV), a member of the flavivirus family, starts to emerge and causes severe human diseases. The World Health Organization (WHO) has declared ZIKV as a global public health emergency. There is currently neither effective vaccine nor specific therapy for ZIKV. For flaviviruses, a single viral polyprotein precursor is synthesized from the viral genome during infection of the host cell. The virus encodes its own protease, which works together with host proteases to cleave the protein precursor into its component proteins. The viral protease is composed of viral proteins NS2B and NS3. This viral protease is essential for virus assembly and replication. Using a high throughput screening assay, we identified several existing drugs, including niclosamide and nitazoxanide, that are potent and broad-spectrum flavivirus inhibitors. These drugs inhibited flavivirus protease via an orthosteric inhibition mechanism, by blocking the interactions between viral protease components NS2B and NS3. The major goal of this proposal is to perform reformulation, in vivo pharmacokinetics and efficacy studies to establish whether these two drugs, niclosamide and nitazoxanide, are effective in ZIKV animal model. These studies are essential for drug repurposing. The approval of new compounds as drugs by governmental drug administration agencies requires significant effort, time, and expense. If drugs that are already approved for treatment have additional capabilities that can be exploited therapeutically, repurposing them is the fastest route to develop new therapies.
翻译后摘要:大多数黄病毒是重要的人类病原体。寨卡病毒(ZIKV),一种成员 黄病毒家族的一种病毒开始出现并引起严重的人类疾病。世界卫生 世界卫生组织(WHO)宣布ZIKV为全球公共卫生紧急事件。目前 没有有效的疫苗或针对ZIKV的特异性治疗。对于黄病毒,单个病毒多蛋白 前体在宿主细胞感染期间从病毒基因组合成。病毒编码 它自己的蛋白酶,它与宿主蛋白酶一起工作,将蛋白质前体切割成 其组成蛋白质。病毒蛋白酶由病毒蛋白NS2B和NS3组成。这种病毒 蛋白酶是病毒装配和复制所必需的。使用高通量筛选测定, 我们确定了几种现有的药物,包括氯硝柳胺和硝唑尼特,它们是有效的, 广谱黄病毒抑制剂。这些药物通过正构作用抑制黄病毒蛋白酶, 抑制机制,通过阻断病毒蛋白酶组分NS2B和 NS3。该提案的主要目标是进行重新配制、体内药代动力学和 疗效研究,以确定这两种药物,氯硝柳胺和硝唑尼特是否有效, 在ZIKV动物模型中。这些研究对于药物再利用至关重要。批准新 政府药物管理机构将化合物作为药物需要大量的努力, 时间和费用。如果已经批准用于治疗的药物具有额外的功能, 可以用于治疗,重新利用它们是开发新的 治疗

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HONGMIN LI其他文献

HONGMIN LI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HONGMIN LI', 18)}}的其他基金

Development of Inhibitors Targeting Flavivirus Methyltransferase
黄病毒甲基转移酶抑制剂的开发
  • 批准号:
    10636605
  • 财政年份:
    2023
  • 资助金额:
    $ 23.55万
  • 项目类别:
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries
通过重新利用药物库发现隐球菌病的治疗方法
  • 批准号:
    10308245
  • 财政年份:
    2019
  • 资助金额:
    $ 23.55万
  • 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
  • 批准号:
    10319642
  • 财政年份:
    2018
  • 资助金额:
    $ 23.55万
  • 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
  • 批准号:
    10376239
  • 财政年份:
    2018
  • 资助金额:
    $ 23.55万
  • 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
  • 批准号:
    10318299
  • 财政年份:
    2018
  • 资助金额:
    $ 23.55万
  • 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
  • 批准号:
    10382470
  • 财政年份:
    2018
  • 资助金额:
    $ 23.55万
  • 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
  • 批准号:
    9538444
  • 财政年份:
    2017
  • 资助金额:
    $ 23.55万
  • 项目类别:
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
  • 批准号:
    9053450
  • 财政年份:
    2015
  • 资助金额:
    $ 23.55万
  • 项目类别:
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
  • 批准号:
    8821943
  • 财政年份:
    2015
  • 资助金额:
    $ 23.55万
  • 项目类别:
The West Nile virus methyltransferase
西尼罗河病毒甲基转移酶
  • 批准号:
    7842651
  • 财政年份:
    2009
  • 资助金额:
    $ 23.55万
  • 项目类别:

相似海外基金

Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334970
  • 财政年份:
    2024
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
  • 批准号:
    2400195
  • 财政年份:
    2024
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334969
  • 财政年份:
    2024
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
  • 批准号:
    23K04919
  • 财政年份:
    2023
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
  • 批准号:
    22KJ2957
  • 财政年份:
    2023
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
  • 批准号:
    23K04494
  • 财政年份:
    2023
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
  • 批准号:
    23K13831
  • 财政年份:
    2023
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
  • 批准号:
    2238379
  • 财政年份:
    2023
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
  • 批准号:
    2154399
  • 财政年份:
    2022
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
  • 批准号:
    RGPIN-2019-06633
  • 财政年份:
    2022
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了